Aroa Biosurgery Ltd (ARX) - Total Assets

Latest as of September 2025: AU$95.27 Million AUD ≈ $67.41 Million USD

Based on the latest financial reports, Aroa Biosurgery Ltd (ARX) holds total assets worth AU$95.27 Million AUD (≈ $67.41 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Aroa Biosurgery Ltd to assess the company's total reinvestment commitment from operating cash flow.

Aroa Biosurgery Ltd - Total Assets Trend (2001–2025)

This chart illustrates how Aroa Biosurgery Ltd's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Aroa Biosurgery Ltd to evaluate the quality of earnings relative to operating cash generation.

Aroa Biosurgery Ltd - Asset Composition Analysis

Current Asset Composition (March 2025)

Aroa Biosurgery Ltd's total assets of AU$95.27 Million consist of 62.6% current assets and 37.4% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 7.3%
Accounts Receivable AU$14.84 Million 15.0%
Inventory AU$7.52 Million 7.6%
Property, Plant & Equipment AU$21.51 Million 21.7%
Intangible Assets AU$12.33 Million 12.5%
Goodwill AU$5.03 Million 5.1%

Asset Composition Trend (2001–2025)

This chart illustrates how Aroa Biosurgery Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Aroa Biosurgery Ltd worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Aroa Biosurgery Ltd's current assets represent 62.6% of total assets in 2025, an increase from 0.0% in 2001.
  • Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 72.2% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2001.
  • Asset Diversification: The largest asset category is property, plant & equipment at 21.7% of total assets.

Aroa Biosurgery Ltd Competitors by Total Assets

Key competitors of Aroa Biosurgery Ltd based on total assets are shown below.

Company Country Total Assets
Shenzhen New Industries Biomedical
SHE:300832
China CN¥9.58 Billion
Inspire Medical Systems Inc
NYSE:INSP
USA $911.38 Million
SS Innovations International Inc. Common Stock
NASDAQ:SSII
USA $90.55 Million
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
China CN¥1.59 Billion
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
China CN¥805.10 Million
Stratec SE
XETRA:SBS
Germany €443.38 Million
Scandinavian Medical Solutions AS
CO:SMSMED
Denmark Dkr205.86 Million
Duearity AB
ST:DEAR
Sweden Skr10.84 Million

Aroa Biosurgery Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 6.52 8.53 12.48
Quick Ratio 5.74 7.31 11.48
Cash Ratio 0.00 0.00 0.00
Working Capital AU$50.46 Million AU$51.90 Million AU$43.17 Million

Aroa Biosurgery Ltd - Advanced Valuation Insights

This section examines the relationship between Aroa Biosurgery Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.74
Latest Market Cap to Assets Ratio 1.56
Asset Growth Rate (YoY) -2.9%
Total Assets AU$98.94 Million
Market Capitalization $154.57 Million USD

Valuation Analysis

Above Book Valuation: The market values Aroa Biosurgery Ltd's assets above their book value (1.56x), reflecting positive investor sentiment about the company's future prospects.

Slight Asset Contraction: Aroa Biosurgery Ltd's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Aroa Biosurgery Ltd (2001–2025)

The table below shows the annual total assets of Aroa Biosurgery Ltd from 2001 to 2025.

Year Total Assets Change
2025-03-31 AU$98.94 Million
≈ $70.01 Million
-2.89%
2024-03-31 AU$101.88 Million
≈ $72.09 Million
-6.60%
2023-03-31 AU$109.07 Million
≈ $77.17 Million
+4.17%
2022-03-31 AU$104.71 Million
≈ $74.09 Million
+43.19%
2021-03-31 AU$73.12 Million
≈ $51.74 Million
-11.40%
2020-03-31 AU$82.54 Million
≈ $58.40 Million
+117.42%
2019-03-31 AU$37.96 Million
≈ $26.86 Million
+165.41%
2018-03-31 AU$14.30 Million
≈ $10.12 Million
+119.53%
2017-03-31 AU$6.52 Million
≈ $4.61 Million
+2.51%
2016-03-31 AU$6.36 Million
≈ $4.50 Million
-15.37%
2015-03-31 AU$7.51 Million
≈ $5.31 Million
-10.66%
2014-03-31 AU$8.41 Million
≈ $5.95 Million
-10.16%
2013-03-31 AU$9.36 Million
≈ $6.62 Million
-14.38%
2012-03-31 AU$10.93 Million
≈ $7.73 Million
+35.33%
2011-03-31 AU$8.07 Million
≈ $5.71 Million
+57.38%
2010-03-31 AU$5.13 Million
≈ $3.63 Million
-93.82%
2009-03-31 AU$83.08 Million
≈ $58.79 Million
+16.03%
2008-03-31 AU$71.60 Million
≈ $50.66 Million
-19.12%
2007-03-31 AU$88.53 Million
≈ $62.64 Million
+118.18%
2006-03-31 AU$40.58 Million
≈ $28.71 Million
+107.03%
2005-03-31 AU$19.60 Million
≈ $13.87 Million
+26.93%
2004-03-31 AU$15.44 Million
≈ $10.93 Million
+27.39%
2003-03-31 AU$12.12 Million
≈ $8.58 Million
-1.97%
2002-03-31 AU$12.37 Million
≈ $8.75 Million
-10.73%
2001-03-31 AU$13.85 Million
≈ $9.80 Million
--

About Aroa Biosurgery Ltd

AU:ARX Australia Medical Devices
Market Cap
$154.57 Million
AU$218.45 Million AUD
Market Cap Rank
#17621 Global
#519 in Australia
Share Price
AU$0.63
Change (1 day)
-2.33%
52-Week Range
AU$0.50 - AU$0.80
All Time High
AU$1.54
About

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more